Chester County News and Community Website
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced third-quarter 2025 financial results and a clinical update highlighting continued progress in its nomlabofusp development program for Friedreich’s ataxia (FA), …
Larimar Reports Promising Friedreich’s Ataxia Data as Nomlabofusp Nears Phase 3 Launch Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported new long-term open-label (OL) data for nomlabofusp in Friedreich’s ataxia (FA), showing sustained increases in frataxin (FXN) protein and consistent …
Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported second-quarter 2025 results, highlighting progress toward a planned Biologics License Application (BLA) for nomlabofusp, a potential first disease-modifying therapy for …
Larimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA Filing Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced the publication of two new peer-reviewed articles detailing nonclinical data supporting the therapeutic potential of its investigational frataxin replacement …
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced an updated timeline for submitting its Biologics License Application (BLA) for nomlabofusp, a potential first-in-class treatment for Friedreich’s Ataxia …
Larimar Therapeutics Aligns with FDA Guidance, Revises Nomlabofusp Submission Timeline Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced a conference call and webcast to discuss regulatory updates for the nomlabofusp clinical development program for Friedreich’s Ataxia on Monday, …
Larimar Therapeutics to Host Conference Call on Friedreich’s Ataxia Updates Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has unveiled its operational and financial results for the first quarter of 2025, showcasing significant progress in its clinical development program …
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced significant progress in its nomlabofusp program for Friedreich’s Ataxia (FA), reporting key regulatory advancements, ongoing clinical developments, and a robust …
Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference, scheduled to take place in Miami Beach, Florida, from …
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for Friedreich’s ataxia (FA), marking an important step in …
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia Read More